Citations 356

MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis

Journal of Neurology, Neurosurgery & Psychiatry | July 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnnp-2025-336684

10.1136/jnnp-2025-336684 | PMID 40685157

Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission. Methods We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (≤30 days) and remission MRI scans (≥12 months) without interval attacks. MRIs were compared between groups for key features. Results We included 43 patients with MOGAD (median age 31 years (range, 3–67); 63% female) and 49 patients with MS (median age 39 years (range, 17–65); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden’s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14/44 (32%) vs 0/60 (0%), p<0.001; spine 21/27 (78%) vs 7/36 (19%), p<0.001). In addition, the presence of T1-hypointense, ovoid periventricular T2, and enhancing lesions were more common in MS versus MOGAD at attack and remission and in the spine, longitudinally extensive T2 lesions were more common in MOGAD attacks (8/27 (30%)). Conclusion Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.
Meningitis as an Attack Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

JAMA Neurology | June 16, 2025 | Volume: 82 | Issue: 8 | Pages: 871

10.1001/jamaneurol.2025.1774 | PMID 40522676

This international multicenter study seeks to determine the frequency and characteristics of meningitis in myelin oligodendrocyte glycoprotein antibody (MOGAD)–associated disease and highlight its pathology.
Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal | May 26, 2025 | Volume: 31 | Issue: 10 | Pages: 1247-1253

10.1177/13524585251340841 | PMID 40415648

Increased intracranial pressure (ICP) is increasingly recognized in myelin oligodendrocyte glycoprotein antibody-associated disease but has not been systematically explored in other demyelinating conditions. This cross-sectional study examines the features of raised ICP in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Lumbar puncture opening pressure (OP) done within 30 days of an attack was identified in 41 NMOSD patients and 37 MS patients. Raised OP was present in 7 (17.1%) NMOSD patients and 4 (10.8%) MS patients who were largely asymptomatic, partially explained by obesity, and did not require ICP lowering medications beyond acute treatment with corticosteroids.
Reply to Letter: Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay

Annals of Clinical and Translational Neurology | May 14, 2025 | Volume: 12 | Issue: 8 | Pages: 1725-1726

10.1002/acn3.70061 | PMID 40368601

Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Neurology | May 5, 2025 | Volume: 104 | Issue: 10 | Pages: No page available

10.1212/wnl.0000000000213557 | PMID 40324120

Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG–Positive NMOSD

JAMA Network Open | April 21, 2025 | Volume: 8 | Issue: 4 | Pages: e255989

10.1001/jamanetworkopen.2025.5989 | PMID 40257801

This case series examines long-term outcomes for 2 aquaporin-4-IgG (AQP4-IgG)–positive patients with neuromyelitis optica spectrum disorder (NMOSD) who underwent autologous hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen and rituximab.
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 16, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1177/20552173251329825 | PMID 40292035

Background Falls in people with multiple sclerosis (pwMS) lead to morbidity and expense. Objective Identify clinical metrics associated with falls. Methods Eighty-six pwMS completed fall surveys, timed 25-foot walk (T25FW), and motion analysis with Clario Opal devices. Logistic regression models were created. Results Median age was 54.5 years (range 21–73), 62% (53) were female. The cohort included 58% with relapsing (50) and 42% with progressive MS (36). Those who reported falling in the last year were older (median age 58 vs 52.5, p = .03) and had a higher Patient Determined Disease Step (PDDS) score (median 3 vs 1, p < .0001). Falls were associated with worse balance metrics including sway area (median 2.3 degrees 2 vs 1.2, p = .01), jerk (median 3.3 m 2 /s 5 vs 1.6, p = .005), and slower T25FW (median 11.5 s vs 8; p < .0001). A multivariable regression model based on gait aid use and T25FW time >10.8 s (c = 0.80) was derived. Having both features portended a probability of falling of 0.97, while having neither, a probability of 0.26. Conclusions Falls in pwMS are more frequent in patients who are older, have higher PDDS, slower walking, and worse balance. Gait aid use and T25FW >10.8 s were strongly associated with falls in the past year.
Effectiveness and Outcome Predictors of Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (S38.004)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210879

Tremor and Disability Outcomes After Deep Brain Stimulation for Multiple Sclerosis-associated Tremor (P12-1.014)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210835

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in Anti-LGI-1 Encephalitis (S7.002)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211378